{"id":39924,"date":"2024-03-03T04:35:42","date_gmt":"2024-03-02T23:05:42","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=39924"},"modified":"2025-04-24T20:56:52","modified_gmt":"2025-04-24T15:26:52","slug":"pharma-pli","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/pharma-pli\/","title":{"rendered":"40 pharma PLI projects launched"},"content":{"rendered":"<h2>What\u2019s in today\u2019s article?<\/h2>\n<ul>\n<li>Why in news?<\/li>\n<li>The pharmaceutical industry in India<\/li>\n<li>What are the notable achievements of the pharmaceutical industry in India?<\/li>\n<li>The pharmaceutical industry in India &#8211; Industry scenario<\/li>\n<li>Support extended by the govt to he pharmaceutical industry in India<\/li>\n<li>News Summary: 40 pharma PLI projects launched<\/li>\n<li>Key highlights of the speech delivered Union Health Minister<\/li>\n<\/ul>\n<h2>Why in news?<\/h2>\n<ul>\n<li>Union govt has inaugurated 27 greenfield bulk drug park projects and 13 greenfield manufacturing plants for medical devices.\n<ul>\n<li>These forty greenfield projects were inaugurated under the PLI schemes for manufacturing bulk drugs and medical devices.\n<ul>\n<li>A bulk drug, also known as an active pharmaceutical ingredient (API), is the chemical substance responsible for the therapeutic effects of a pharmaceutical product.<\/li>\n<li>i.e., it is the primary ingredient in a medication that produces the intended medical effect.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2>The pharmaceutical industry in India: Notable achievements<\/h2>\n<ul>\n<li>The Indian pharmaceutical industry, often referred to as \u2018<u>the pharmacy of the world\u2019<\/u>, contributes immensely to global public health and promoting universal healthcare access.<\/li>\n<li><u>India ranks 3rd worldwide for production by volume and 14th by value<\/u>.<\/li>\n<li>India is the <u>largest provider of generic medicines<\/u> globally, occupying a 20% share in global supply by volume.\n<ul>\n<li>The pharmaceutical industry in India offers 60,000 generic brands across 60 therapeutic categories.<\/li>\n<\/ul>\n<\/li>\n<li>It is the leading vaccine manufacturer globally with 60% of the world\u2019s vaccines comes from India.<\/li>\n<\/ul>\n<h2>Industry scenario<\/h2>\n<ul>\n<li>Foreign Direct Investment (FDI)\n<ul>\n<li>100% FDI in the Pharmaceutical sector is allowed under the automatic route for greenfield pharmaceuticals.<\/li>\n<li>100% FDI in the pharmaceutical sector is allowed in brownfield pharmaceuticals; wherein <u>74% is allowed under the automatic route<\/u> and thereafter through the government approval route.<\/li>\n<\/ul>\n<\/li>\n<li>Market Size\n<ul>\n<li>The pharmaceutical industry in India is valued at $50 bn in 2022-23 and exports accounting for 50% of the production.\n<ul>\n<li>It is expected to reach $65 bn by 2024 and to $130 bn by 2030.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>Export\n<ul>\n<li>India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports.<\/li>\n<li>India supplies over 50% of Africa\u2019s requirement for generics, ~40% of generic demand in the US and ~25% of all medicine in the UK.<\/li>\n<li>For the period 2021-22, export of drugs and pharma products stood at $24.6 bn compared to $24.44 bn as of 2020-21.<\/li>\n<li>The Indian pharma industry witnessed exponential growth of 103% during 2014-22 from $11.6 bn to $24.6 bn.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2>Support extended by the govt<\/h2>\n<ul>\n<li>PLI scheme\n<ul>\n<li>PLI for Pharmaceuticals:\n<ul>\n<li>The scheme was launched with an outlay of INR 15,000 Cr until FY 2027-28.<\/li>\n<li>The aim is to boost India\u2019s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods.<\/li>\n<\/ul>\n<\/li>\n<li>PLI for Promoting Domestic Manufacturing of Medical Devices\n<ul>\n<li>The scheme, with an outlay of INR 3420 Cr till FY 2027-28, is being provided for the creation of common testing and laboratory facilities\/centres in four Medical Device Parks.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>Vision Pharma 2047\n<ul>\n<li>Make India a global leader in the manufacturing of affordable, innovative &amp; quality pharmaceuticals &amp; medical devices for the goal of Vasudhaiva Kutumbakam<\/li>\n<li>Vishwaguru in innovation &amp; Research for delivering health care products to future generations in a sustainable manner, introducing natural products<\/li>\n<li>Medical Devices to be an integral part of global supply chains for raw materials, components, spare parts, assemblies\/subassemblies, etc.<\/li>\n<li>Digitisation and technology upgradation in the delivery of services &amp; products under Jan Aushadhi Pariyojana<\/li>\n<\/ul>\n<\/li>\n<li>National Pharmaceutical Policy (2023)\n<ul>\n<li>The policy is being drafted to serve as a comprehensive framework to address the challenges faced by Indian Pharmaceutical industries.<\/li>\n<li>The draft policy encompasses five key pillars:\n<ul>\n<li>Fostering Global Pharmaceutical Leadership, Promoting Self-Reliance, Advancing Health Equity and accessibility, Enhancing Regulatory Efficiency in the Indian Pharmaceutical Sector and Attracting investments.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>Scheme for Strengthening of Pharmaceuticals Industry (2022)\n<ul>\n<li>The scheme, launched with a total financial outlay of INR 500 Cr until FY 2025-26 to:\n<ul>\n<li>strengthen the existing pharmaceutical clusters\u2019 capacity by creating common facilities;<\/li>\n<li>facilitate MSMEs of a proven track record to meet regulatory standards; and<\/li>\n<li>facilitate growth and development of Pharmaceutical and Medical Devices Sectors.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>Scheme for Promotion of Bulk Drug Parks (2020)\n<ul>\n<li>The scheme boosts domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector.<\/li>\n<li>Financial assistance, up to INR 1000 Cr, will be provided for the creation of common infrastructure facilities in three Bulk Drug Parks selected in Gujarat, Himachal Pradesh, and Andhra Pradesh.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2>News Summary: 40 pharma PLI projects launched<\/h2>\n<ul>\n<li>Forty greenfield projects under the PLI schemes for manufacturing bulk drugs and medical devices were inaugurated by the government.<\/li>\n<li>This included 27 greenfield bulk drug projects and 13 manufacturing plants for medical devices.<\/li>\n<\/ul>\n<h2>Key highlights of the speech delivered Union Health Minister<\/h2>\n<ul>\n<li>Highlighted importance of PLI scheme in Pharma\n<ul>\n<li>The PLI scheme\u2019s success has reduced India\u2019s dependence on imports for medicines, API and medical devices.<\/li>\n<li>Instead of importing goods worth Rs 75,000 crore, the country will now be exporting drugs and products worth Rs 75,000 crore.\n<ul>\n<li>The department of pharmaceuticals is implementing three PLI schemes \u2014 pharmaceuticals, bulk drugs and medical devices.<\/li>\n<li>For the PLI scheme for pharmaceuticals, the government has approved 55 applicants with an incentive outlay of Rs 15,000 crore.<\/li>\n<li>As many as 138 products from 26 PLI applicants have been approved for greenfield manufacturing of medical devices with an outlay of Rs 3,420 crore.<\/li>\n<li>The bulk drugs PLI includes manufacturing 41 bulk drugs with a total outlay of Rs 6,940 crore.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>Revival of drug manufacturing\n<ul>\n<li>He cited the example of Penicillin G, which India had stopped making for the last 30 years after large-scale dumping led to plants shutting down.<\/li>\n<li>Penicillin G will now be made in the country, with the plant expected to be operational in June 2024.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<hr \/>\n<h3>Q1)\u00a0What is Penicillin G?<\/h3>\n<p>Penicillin G, also known as benzylpenicillin, is an antibiotic used to treat and prevent bacterial infections. It&#8217;s a narrow-spectrum antibiotic that works by killing bacteria that cause infections.<\/p>\n<h3>Q2) What are bulk drugs or APIs?<\/h3>\n<p>\u00a0A bulk drug, also called an active pharmaceutical ingredient (API), is the key ingredient of a drug or medicine, which lends it the desired therapeutic effect or produces the intended pharmacological activity. For example, paracetamol is a bulk drug, which acts against pain. It is mixed with binding agents or solvents to prepare the finished pharmaceutical product, ie a paracetamol tablet, capsule or syrup, which is consumed by the patient.<\/p>\n<hr \/>\n<p><strong>Source: <\/strong><a href=\"https:\/\/www.financialexpress.com\/business\/industry-40-pharma-pli-projects-launched-3411681\/\" target=\"_blank\" rel=\"nofollow noopener\"><u>40 harma PLI projects launched<\/u><\/a><u> | <\/u><a href=\"https:\/\/pib.gov.in\/PressReleaseIframePage.aspx?PRID=2010924\" target=\"_blank\" rel=\"nofollow noopener\"><u>PIB<\/u><\/a><u> | <\/u><a href=\"https:\/\/www.investindia.gov.in\/team-india-blogs\/pharmaceutical-sector-spotlight-driving-innovation-india\" target=\"_blank\" rel=\"nofollow noopener\"><u>Invest India<\/u><\/a><u> | <\/u><a href=\"https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/will-indias-pharma-sector-be-able-to-come-out-of-its-china-dependence\/articleshow\/108048363.cms?from=mdr\" target=\"_blank\" rel=\"nofollow noopener\"><u>Economic Times<\/u><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Indian pharmaceutical industry is often referred to as \u2018the pharmacy of the world\u2019.<\/p>\n","protected":false},"author":5,"featured_media":39925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18],"tags":[],"class_list":{"0":"post-39924","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-mains-current-affairs","8":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/39924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=39924"}],"version-history":[{"count":0,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/39924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/39925"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=39924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=39924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=39924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}